Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.25%
#3 Bitway Bitway +11.68%
#4 Glidr Glidr +9.69%
#5 Meteora Meteora +9.51%
#6 OPENLOOT OPENLOOT +8.29%
#7 Unit Pump Unit Pump +8.17%
#8 Pump.fun Pump.fun +8.17%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.80%
#10 eCash eCash +7.48%
Coin of the day
PulseChain PulseChain
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Classificação em ações #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Preço da ação
$0.55
Última sincronização: 2025-02-11
Valor de mercado
$28.90M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Marinus Pharmaceuticals, Inc. (MRNS)

Categoria

Healthcare
Receita da Marinus Pharmaceuticals, Inc. (MRNS)
Receita em Sep 2024 TTM: $31.47M
De acordo com os últimos relatórios financeiros da Marinus Pharmaceuticals, Inc., a receita atual da empresa (TTM) é $31.47M. Em 2022, a empresa obteve uma receita de $25.48M um aumento em relação a a receita do ano 2021, que foi de $15.35M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Marinus Pharmaceuticals, Inc. de 2012 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH